ロード中...
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10–35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point muta...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5610029/ https://ncbi.nlm.nih.gov/pubmed/28969097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19925 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|